Accelerate Diagnostics Inc (AXDX) Shares Sold by Axa
Axa cut its stake in shares of Accelerate Diagnostics Inc (NASDAQ:AXDX) by 28.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 311,020 shares of the medical research company’s stock after selling 121,627 shares during the quarter. Axa’s holdings in Accelerate Diagnostics were worth $8,149,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors also recently made changes to their positions in the business. Cpwm LLC purchased a new position in shares of Accelerate Diagnostics during the fourth quarter worth approximately $202,000. UBS Asset Management Americas Inc. purchased a new position in shares of Accelerate Diagnostics during the fourth quarter worth approximately $233,000. Teacher Retirement System of Texas purchased a new position in shares of Accelerate Diagnostics during the fourth quarter worth approximately $292,000. Thompson Investment Management Inc. purchased a new position in shares of Accelerate Diagnostics during the third quarter worth approximately $393,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Accelerate Diagnostics by 13.0% during the second quarter. The Manufacturers Life Insurance Company now owns 21,125 shares of the medical research company’s stock worth $578,000 after acquiring an additional 2,425 shares in the last quarter. Institutional investors and hedge funds own 44.86% of the company’s stock.
Accelerate Diagnostics Inc (NASDAQ:AXDX) opened at $25.40 on Wednesday. Accelerate Diagnostics Inc has a one year low of $16.75 and a one year high of $30.45. The company has a market cap of $1,420.00, a price-to-earnings ratio of -21.53 and a beta of 2.22.
In other news, Director Jack W. Schuler bought 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 22nd. The shares were bought at an average cost of $25.21 per share, with a total value of $252,100.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Jack W. Schuler bought 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The stock was purchased at an average cost of $24.95 per share, for a total transaction of $499,000.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 45,100 shares of company stock worth $1,130,850. 50.00% of the stock is owned by insiders.
Several research analysts have commented on the stock. BidaskClub raised shares of Accelerate Diagnostics from a “hold” rating to a “buy” rating in a research note on Thursday, February 22nd. Zacks Investment Research downgraded shares of Accelerate Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. ValuEngine raised shares of Accelerate Diagnostics from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, BTIG Research downgraded shares of Accelerate Diagnostics from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 13th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $33.00.
WARNING: This story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2018/03/14/accelerate-diagnostics-inc-axdx-shares-sold-by-axa.html.
About Accelerate Diagnostics
Accelerate Diagnostics, Inc is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company’s in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic.
Want to see what other hedge funds are holding AXDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accelerate Diagnostics Inc (NASDAQ:AXDX).
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.